Standard and Emerging Treatment Options for Diabetic Neuropathy

Author(s): Nicholas Tentolouris, Kleopatra Alexiadou, Konstantinos Makrilakis, Stavros Liatis, Edward Jude, Andrew J. Boulton.

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 22 , 2014

Become EABM
Become Reviewer

Abstract:

Diabetic neuropathy is a common complication of diabetes mellitus affecting 30-50% of patients and is a major cause for increased costs, morbidity and mortality. Strict diabetes control prevents this complication and may restore neurologic deficits in the early stages. Several efforts have been undertaken to alter the natural history of this complication, including the use of aldose reductase and protein kinase-C inhibitors, as well as antioxidants. Available data so far do not support the use of aldose reductase inhibitors due to safety issues and efficacy. Protein kinase-C inhibitors have provided encouraging initial results but their development has been halted. Antioxidants, like a-lipoic acid, improve some neurological deficits and painful symptoms. There are effective and safe medications such as anticonvulsants, antidepressants and opioids for the management of patients with painful symptoms. In this revew we present standard and emerging treatment modalities for the etiologic and symptomatic treatment of diabetic neuropathy.

Keywords: Diabetic neuropathy, etiologic treatment, symptomatic treatment, aldose reductase inhibitors, protein kinase-C inhibitors, antioxidants, antidepressants, anticonvulsants.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 22
Year: 2014
Page: [3689 - 3704]
Pages: 16
DOI: 10.2174/13816128113196660682
Price: $58

Article Metrics

PDF: 26